top of page

19th IDS Congress
Paris 2023

23-27 May. 2023

The Immunology of Diabetes Society (IDS) is a scientific society dedicated to improving understanding and treatment of type 1 diabetes. IDS organizes a Congress every 18 months in major centres in Europe, North America and Asia/Oceania at which there are scientific presentations to further this goal.

Centre international de Conférences Sorbonne Université

4 place Jussieu - 44-55

75005 - Paris, France

logo ids_edited.jpg
*To submit before 15th February 2023

Confirmed Speakers

(by alphabetical order)

Peter Achenbach, Coralie Alabert, Mark Atkinson, Jean-François Bach, Burkhard Becher, Polly Bingley, Ezio Bonifacio, Marcela Brissova, Todd Brusko, Yi-Chun Chen, Jenny Couper, Mark M. Davis, Colin Dayan, Gerard Eberl, Decio L. Eizirik, Donna Farber, Carla Greenbaum, John Harris, Len Harrison, Matthias Hebrok, Kevan Herold, Heikki Hyoty, Eddie James, Matthew Johnson, Sally Kent, David Klatzmann, Jeffrey Krischer, Vito Lampasona, Peter E. Lipsky, Chantal Mathieu, Eoin McKinney, Cristina Nostro, Timo Otonkoski, Alberto Pugliese, Frédéric Rieux-Laucat, Bart Roep, Miguel Sanjuan, Pere Santamaria, Andrea Schietinger, Anath Shalev, Jeannette Soderberg, Tommi Suvitaival, Qizhi Tang, Timothy Tree, Taylor Triolo, Tommi Vatanen, Joseph Vieth, Carola Vinuesa, John Wentworth, Benjamin Youngblood, Tong Yue, Anette Ziegler

Schedule Thu 25th

 Thursday 25th

8.20 am

12.00 - 1.00 pm

Plenary 3

Stem-like autoimmune CD8+ T cells: Andrea Schietinger (Sloan Kettering, New York)

T-Cell Workshop session – Chairs: Sally Kent, Eddie James

9.00 am

12.00 - 1.30 pm

Short Symposium 3: Theme to be defined

Talk 15

Talk 16

Oral Abstract 13

Oral Abstract 14

Oral Abstract 15

9.00 - 10.30 am

Parallel session: Editorial tips in academic publishing

Jennifer Sargent, Deputy Editor Nature Medicine

Marta Koch, Editor-in-Chief Lancet Diabetes Endocrinology

10.30 - 11 am

Parallel session : Improving the design of clinical trials in T1D: analysis of data from the Trial Outcome Markers Initiative (TOMI) collaboration - Room 109, barre 44-54, 1st floor.

The Trial Outcome Marker Initiative (TOMI) brings together data from >10,000 individuals with new-onset T1D including 2,900 from 21 different clinical trials. Analysis of C-peptide, HbA1c and composite outcomes will be discussed, which has provided significant insights into designing clinical trials for stage 3 T1D

1.00 - 2.00 pm

11.00 am

Short Symposium 4: Fresh ideas from early researchers, session led by PhD candidates/Postdoc scientists – Coordinators: Alice Long, Teresa Rodriguez-Calvo

*3 puzzling findings that we would like to understand

*3 outstanding questions that we would like to see addressed in T1D research, and how

2.00 pm

4.30 - 5.00 pm

IDS General Assembly

5.00 pm 

2.30 pm

Consortia roundtable, “pulling it all together”: 3 things we have learned / we expect to learn from other consortia – synergies and opportunities

nPOD (A. Pugliese), INNODIA (C. Matthieu), TrialNet (K. Herold), ITN (J. Nepom), ENDIA (J. Couper), GPPAD (A. Ziegler), TEDDY (J. Krischer).

6.30 pm 

Long Symposium 4: Common themes in autoimmunity

Talk 17: Autoimmune heterogeneity and gene variants: Carola Vinuesa (Francis Crick Institute, London)

Talk 18: Vitiligo: John Harris (Umass, Worchester)

Talk 19: Immune and target cell cross-talk in autoimmune diseases: Decio Eizirik (ULB, Brussels)

Talk 20: Drug repurpusing in autoimmune diseases: Peter Lipsky (Ampel Biosolutions, Charlottesville)

Oral Abstract 16

6.30 - 7.30 pm
Time on your own

7.30 pm

IDS Gala evening

bottom of page